<pre id="9dp3j"><big id="9dp3j"><ruby id="9dp3j"></ruby></big></pre>

    <span id="9dp3j"><track id="9dp3j"></track></span>
    <track id="9dp3j"></track>

      <big id="9dp3j"><sub id="9dp3j"><listing id="9dp3j"></listing></sub></big>

        <track id="9dp3j"></track>

        <ol id="9dp3j"></ol>


          創新與研發



          R&D


          創新平臺


          長森藥業專注具有自主知識產權及國際領先水平的創新藥物的開發和醫學轉化,擁有一支由國際知名藥學專家領銜,多名資深海歸博士帶隊的高水平研發團隊。

          長森藥業聚焦臨床未竟需求,開發First in Class(FIC)、Best in Class(BIC)的創新產品,研發團隊擁有從候選藥物設計立項到藥物上市的完整產業鏈經驗,對免疫治療具有深刻的理解和獨特的洞見,針對自免疫相關的激酶等相關靶點深耕多年,擅長高活性與高選擇性導向的創新藥設計,研究與開發;同時,研發團隊還具備豐富的大規模商業化生產的工藝設計和路線規劃經驗,對全球藥物合作開發的深度理解及Licensing Out影響力和資源整合效率。

          長森藥業已有2款候選藥物在臨床研究階段,研發管線儲備豐富。

          Innovation Platform

           

          Longwood Biopharma focuses on the development and medical translation of world-class innovative drugs with independent IPR. The company has a high-level R&D team led by world-renowned experts and a number of senior PhD.

          Our R&D team has a deep understanding and unique insight of immunotherapy, and has been working on autoimmune-related kinases and other related targets for many years, specializing in the design, research and development of highly active and highly selective innovative drugs. Furthermore, the R&D team has rich experience in drug synthesis process and route design for large scale manufacturing, in-depth understanding of global drug co-development, and the efficiency of Licensing Out and resource integration.

          The company has strong R&D pipelines with two drug candidates in clinical research stage.

          研發管線

           

          長森藥業聚焦自身免疫疾病、腫瘤免疫、抗病毒等領域的創新藥研發與產業化,管線產品臨床評估指標均達到國際領先水平,有望成為相關領域的重大突破FIC(first in class)。

          領域
          項目
          靶點
          適應癥
          化合物篩選
          化合物優化
          藥效學研究
          毒理學研究
          IND
          臨床 1 期
          臨床 2 期
          乙肝
          LW231
          Capsid
          慢性乙肝
          類風濕性關節炎
          強直性脊柱炎
          白癜風(口服)
          自身免疫疾病
          LW402
          JAK1
          腸炎(克羅恩病)
          銀屑病(口服)
          斑禿(口服)
          特應性皮炎(口服)
          腫瘤免疫
          LW1005
          PD-L1
          腫瘤
          腫瘤、細胞凋亡
          LW108
          MDM2
          腫瘤

          Pipeline

           

          Longwood Biopharma is focusing on the development and industrialization of innovative drugs for autoimmune diseases, tumor immunotherapy and anti-virus. With world-class performance in clinical evaluation, our pipelines are expected to become a major breakthrough in related fields (FIC, first in class).

          Field
          Project
          Target
          Indication
          Compound Screening
          Compound Optimization
          PK/PD Studies
          Toxicology Studies
          IND
          Phase 1
          Phase 2
          HBV
          LW231
          Capsid
          Chronic HBV
          Rheumatoid Arthritis
          Ankylosing Spondylitis
          Vitiligo(Oral)
          Autoimmune diseases
          LW402
          JAK1
          Enteritis(Crohn's Syndrome)
          Psoriasis(Oral)
          Alopecia Areata(Oral)
          Atopic Dermatitis(Oral)
          Immunotherapy
          LW1005
          PD-L1
          Tumor
          Apoptosis
          LW108
          MDM2
          Tumor

          戰略合作


          聯合全球產業伙伴,開展多層次合作,滿足臨床未竟需求


          長森藥業專注于研究開發及商業化創新免疫治療藥物,以滿足中國和全球的臨床需求。

          長森藥業秉承合作共贏的理念,通過與國內外知名高校、產業創新伙伴建立廣泛的合作關系,積極參與全球藥物創新與產業化合作?,F階段,長森藥業期待來自全球的科研機構、產業伙伴在藥物發現、臨床研究、商業化等各階段開展合作,并愿意在合作中開展任何形式的創新合作探索。

          詳情請發郵件至 info@lwbiopharma.com。

          Collaboration

           

          Multi-level Collaboration With Global Industry Partners To Meet Unmet Clinical Needs

          Longwood Biopharma is focused on the R&D and commercialization of innovative immunotherapy drugs to meet clinical needs in China and globally.

          Adhering to the concept of win-win cooperation, Longwood Biopharma actively participates in global drug innovation and industrialization cooperation by establishing extensive partnerships with renowned universities and industrial innovation partners at home and abroad. Presently, we are looking forward to cooperation with research institutions and industrial partners from all over the world in all stages of drug discovery, clinical research and commercialization, and are willing to explore any form of innovative cooperation in the collaboration.

          For more information, please send an email to info@lwbiopharma.com